Universitaetsklinikum Ulm AöR — Sponsor Intelligence | 8 EU Trials

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

3 Recruiting

4 Completed trials

9 Countries active

21 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 3 Phase II: 4 Phase IV: 1

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Splenic marginal zone lymphoma 2 Extranodal marginal zone B-cell lymphoma (MALT type) 2 Nodal marginal zone B-cell lymphoma 2 Marginal zone lymphoma 2 Waldenstrom's macroglobulinaemia 1 Adenocarcinoma pancreas 1 HER2 positive breast cancer 1 Carbohydrate antigen 19-9 1 Breast cancer 1

Top IMPs

ABEMACICLIB 1 CARFILZOMIB 1 CYTARABINE, DAUNORUBICIN 1 EPCORITAMAB 1 IBRUTINIB 1 OBINUTUZUMAB 1 TRASTUZUMAB DERUXTECAN 1 VENETOCLAX 1

All trials

8 total

Epcoritamab in Relapsed/Refractory Marginalzone Lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (EPOS-1) Pending

2025-524879-23-00 Phase II 1 country EPCORITAMAB
Using lab-grown mini-tumors from pancreatic cancer tissue to predict and improve post-surgery treatment for pancreatic cancer Recruiting

2023-510490-34-00 Phase II 1 country
SURVIVE HERoes – A randomized Secondary Adjuvant Treatment Intervention study comparing Trastuzumab-Deruxtecan to SOC therapy in eBC Patient… Recruiting

2024-516173-76-01 Phase III 1 country TRASTUZUMAB DERUXTECAN
A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Di… Recruiting

2023-507518-28-00 Phase III 8 countries VENETOCLAX
Combination of Abemaciclib and endocrine therapy in hormone receptor positive HER2 negative locally advanced or metastatic breast cancer wit… Ended

2024-511209-49-00 Phase IV 1 country ABEMACICLIB
Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) Ended

2024-511929-60-00 Phase II 3 countries CARFILZOMIB; IBRUTINIB
Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno… Ended

2023-503670-21-00 Phase III 2 countries CYTARABINE, DAUNORUBICIN
Obinutuzumab in marginal zone lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (OLYMP-1) Ended

2024-517476-38-00 Phase II 1 country OBINUTUZUMAB

Showing 1–8 of 8 trials

← All sponsors A–Z